Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.